The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Show other versions (1)

BACKGROUND: Vaccination against tuberculosis (TB) should provide long-term protective immunity against Mycobacterium tuberculosis (M.tb). The current TB vaccine, Bacille Calmette-Guerin (BCG), protects against disseminated childhood TB, but protection against lung TB in adolescents and adults is var...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Tameris, M, Geldenhuys, H, Luabeya, A, Smit, E, Hughes, J, Vermaak, S, Hanekom, W, Hatherill, M, Mahomed, H, Mcshane, H, Scriba, T
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2014

Antzeko izenburuak

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
nork: Tameris, M, et al.
Argitaratua: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
nork: Michele Tameris, et al.
Argitaratua: (2014-01-01)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
nork: Bunyasi, E, et al.
Argitaratua: (2017)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
nork: Hawkridge, T, et al.
Argitaratua: (2008)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
nork: Mcshane, H, et al.
Argitaratua: (2016)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
nork: Scriba, T, et al.
Argitaratua: (2011)

The role of clinical symptoms in the diagnosis of intrathoracic tuberculosis in young children
nork: Mcshane, H, et al.
Argitaratua: (2015)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.
nork: Matsumiya, M, et al.
Argitaratua: (2014)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
nork: Tameris, MD, et al.
Argitaratua: (2013)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
nork: Matsumiya, M, et al.
Argitaratua: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
nork: Thomas, Z, et al.
Argitaratua: (2014)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial
nork: Tameris, MD, et al.
Argitaratua: (2013)

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
nork: Scriba, T, et al.
Argitaratua: (2012)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
nork: Mcshane, H
Argitaratua: (2008)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
nork: Harris, SA, et al.
Argitaratua: (2014)

Risk of disease after isoniazid preventive therapy for mycobacterium tuberculosis exposure in young HIV uninfected children
nork: Mcshane, H, et al.
Argitaratua: (2015)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
nork: Meyer, J, et al.
Argitaratua: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
nork: Riste, M, et al.
Argitaratua: (2021)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
nork: Meyer, J, et al.
Argitaratua: (2013)

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.
nork: Schmidt, B, et al.
Argitaratua: (2017)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
nork: Odutola, A, et al.
Argitaratua: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
nork: Odutola, A, et al.
Argitaratua: (2012)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
nork: Rowland, R, et al.
Argitaratua: (2012)

Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: A phase 2 randomized controlled trial.
nork: Nemes, E, et al.
Argitaratua: (2017)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
nork: Pathan, A, et al.
Argitaratua: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
nork: Dieye, T, et al.
Argitaratua: (2013)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
nork: Pathan, A, et al.
Argitaratua: (2012)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
nork: Wajja, A, et al.
Argitaratua: (2017)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
nork: Owiafe, P, et al.
Argitaratua: (2012)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
nork: Harris, S, et al.
Argitaratua: (2011)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
nork: Brookes, R, et al.
Argitaratua: (2008)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
nork: Mcshane, H, et al.
Argitaratua: (2005)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
nork: Michael Riste, et al.
Argitaratua: (2021-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
nork: Anne Wajja, et al.
Argitaratua: (2017-05-01)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
nork: Minassian, A, et al.
Argitaratua: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
nork: Harris, S, et al.
Argitaratua: (2013)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
nork: Tandakha N Dieye, et al.
Argitaratua: (2013-01-01)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
nork: Roger H Brookes, et al.
Argitaratua: (2008-08-01)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
nork: Tandakha N. Dieye, et al.
Argitaratua: (2013-01-01)

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.
nork: Tameris, M, et al.
Argitaratua: (2013)